Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for lysosomal storage disorders--a clinical perspective.

Janice M Fletcher1

  • 1Department of Genetic Medicine, Women's and Children's Hospital, 72 King William Rd, North Adelaide, South Australia, 5006, Australia.

Journal of Inherited Metabolic Disease
|June 10, 2006
PubMed
Summary

Newborn screening for lysosomal storage diseases (LSDs) is feasible due to available therapies and multiplex technology. Early diagnosis is crucial for effective treatment, presenting a scientific challenge in predicting disease severity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extending the new era of genomic testing into pregnancy management: A proposed model for Australian prenatal services.

The Australian & New Zealand journal of obstetrics & gynaecology·2024
Same author

Isolated autism is not an indication for Smith-Lemli-Opitz syndrome biochemical testing.

Journal of paediatrics and child health·2021
Same author

Fatal perinatal mitochondrial cardiac failure caused by recurrent <i>de novo</i> duplications in the <i>ATAD3</i> locus.

Med (New York, N.Y.)·2021
Same author

Mono-symptomatic Fabry disease in a population with mild-to-moderate left ventricular hypertrophy.

Molecular genetics and metabolism reports·2020
Same author

Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.

JIMD reports·2020
Same author

Identification and targeted management of a neurodegenerative disorder caused by biallelic mutations in SLC5A6.

NPJ genomic medicine·2019

Area of Science:

  • Biomedical science
  • Genetics
  • Public health

Background:

  • Therapies for lysosomal storage diseases (LSDs) are available.
  • Animal studies show early diagnosis improves therapy outcomes.
  • The incidence of LSDs is approximately 1 in 7000, making screening feasible.

Purpose of the Study:

  • To discuss newborn screening for LSDs.
  • To highlight the importance of early diagnosis for optimal therapy.
  • To address the scientific challenge of predicting disease severity.

Main Methods:

  • Utilizing multiplex technology for initial screening.
  • Reviewing scientific literature on LSDs and newborn screening.
  • Considering perspectives from scientists, families, communities, and clinicians.

Related Experiment Videos

Main Results:

  • Newborn screening for LSDs is technically feasible with multiplex technology.
  • Early diagnosis is critical for effective therapeutic intervention.
  • Predicting disease severity remains a key scientific challenge.

Conclusions:

  • Newborn screening for LSDs is a viable public health initiative.
  • Integrating screening into existing programs requires careful consideration of all stakeholders.
  • Further research is needed to refine early prediction of disease severity to guide therapy choices.